Product Description
Phosphate Binder to Reduce Hyperphosphatemia. (Sourced from: https://clinicaltrials.gov/study/NCT06218290?term=oxylanthanum%20carbonate&rank=1)
Mechanisms of Action: Phosphate Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Unicycive Therapeutics
Company Location: LOS ALTOS CA 94022
Company CEO: Shalabh Gupta
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|